Gadobutrolo shortage status
1 active shortage notice across 1 country.
Last updated 17 Sept 2026 · sourced from official medicines regulators
- Generic name (INN)
- Gadobutrolo
- Brand names
- Gadovist
- Class
- Auto-created by Agenzia Italiana del Farmaco — Carenze scraper
Where Gadobutrolo is in shortage
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| United States | medium | 1 | 30 Jun 2026 | — | FDA |
Why Gadobutrolo is in shortage
- product discontinuation — e.g. “Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by…” (United States)
Recent shortage history
- Italy: resolved 1 Sept 2026 (began 1 Sept 2026)
- Australia: resolved 28 Aug 2026 (began 29 Jun 2026)
- Italy: resolved 30 Apr 2019 (began 30 Apr 2019)
Frequently asked questions
Is Gadobutrolo currently in shortage?
Yes. As of the latest regulator updates, Gadobutrolo has 1 active shortage notice across 1 country (United States). Status is refreshed daily from official regulatory sources.
Why is Gadobutrolo in shortage?
Regulators attribute the current Gadobutrolo shortages to product discontinuation. The exact cause varies by country and product — each notice on this page links to the official source.
Where does this Gadobutrolo shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Get alerted when Gadobutrolo status changes
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.